Tucked in the first intron of the interleukin-6 receptor gene, rs4845625 does not change a single amino acid — but it doesn't have to. This intronic variant¹¹ intronic variant
Intronic variants can act as cis-regulatory elements that alter transcription factor binding, splicing enhancer activity, or overall gene expression without touching the coding sequence sits within a haplotype block that shapes IL-6 receptor expression levels and, consequently, how strongly IL-6 signaling propagates through the JAK1/STAT3 axis. Its main clinical relevance is threefold: cardiovascular risk, inflammatory biomarker levels, and — most distinctively — response to tocilizumab and sarilumab, the IL-6 receptor-blocking biologics used in rheumatoid arthritis and other autoimmune conditions.

The Mechanism

IL6R encodes the alpha subunit (CD126) of the interleukin-6 receptor, which pairs with the co-receptor gp130 (IL6ST) to initiate JAK/STAT signaling. The rs4845625 variant lies in intron 1 of IL6R at chr1:154,449,591 (GRCh38), approximately 5 kb upstream of the well-characterised missense variant Asp358Ala (rs2228145). The two SNPs are in partial linkage disequilibrium²² partial linkage disequilibrium
Linkage disequilibrium (LD) means nearby variants are inherited together more often than by chance. Partial LD means they co-segregate frequently but not always — some chromosomes carry one without the other and tag overlapping but non-identical haplotypes across the IL6R locus.

The T allele at rs4845625 forms part of a haplotype (rs4845625*T / rs4537545*C) associated with elevated classical IL-6 signaling tone. While the exact molecular mechanism — altered splicing, transcription factor binding affinity, or expression level — has not been precisely characterised at this variant, the downstream phenotypic consequences point consistently toward subtly enhanced pro-inflammatory classical IL-6 signaling rather than the trans-signaling shift driven by Asp358Ala.

The Evidence

The clearest mechanistic fingerprint comes from an Arguinano et al. population study³³ Arguinano et al. population study
Arguinano AA et al., Genes & Immunity 2017; European population cohort examining IL6R haplotypes and multiple cardiometabolic biomarkers. The rs4845625*T / rs4537545*C haplotype was independently associated with simultaneously elevated CRP (p=0.011), LDL cholesterol (p=0.007), and apolipoprotein B (p=0.009). The rs4845625 SNP alone explained 3.49% of LDL-C variance and 5.57% of ApoB variance — a modest but statistically robust independent effect on cardiometabolic risk markers.

A cardiac electrophysiology study⁴⁴ cardiac electrophysiology study
Wu G et al., PLoS One 2014; 278 consecutive patients undergoing catheter ablation for atrial fibrillation in a Chinese Han population found that the T allele substantially increased the risk of AF recurrence both early (OR 1.84, 95% CI 1.31–2.59, p=4.1×10⁻⁴ within 4 weeks) and late (OR 1.92, 95% CI 1.30–2.81, p=0.001 at 3–12 months) after ablation, independent of age, sex, hypertension, and diabetes. AF recurrence after ablation is partly driven by persistent atrial inflammation, making IL-6 receptor variation a plausible mechanistic candidate.

The pharmacogenomic evidence spans two related studies from the same Spanish group. Sainz et al. (Pharmaceutics 2022)⁵⁵ Sainz et al. (Pharmaceutics 2022)
88 RA patients on tocilizumab IV, retrospective cohort at 6 months; six IL6R variants tested found that rs4845625 was the only variant among six IL6R SNPs tested to be associated with all three treatment response measures at six months. A follow-up toxicity study⁶⁶ toxicity study
Sainz et al., J Pers Med 2022; same 88-patient cohort, adverse event analysis found rs4845625 was specifically associated with dyslipidemia as a tocilizumab adverse event — consistent with the variant's independent effect on LDL and ApoB. In a separate sarilumab cohort⁷⁷ sarilumab cohort
Sainz et al., Arthritis Res Ther 2023; 62 RA patients on subcutaneous sarilumab, rs4845625 again emerged as a significant predictor of treatment response, suggesting the association extends across IL-6R-blocking drug classes.

Practical Actions

The T allele's combination of elevated LDL, ApoB, and CRP — together with its association with AF recurrence and CAD risk — makes standard lipid and inflammatory monitoring more important for TT homozygotes and CT heterozygotes. In the pharmacogenomic context, clinicians initiating tocilizumab or sarilumab in T-allele carriers should monitor lipid panels more closely, as the variant is associated with both dyslipidemia adverse events and differential treatment response. The evidence is currently at the level of replicated associations rather than clinical guidelines; no CPIC or DPWG recommendations exist for this intronic variant.

Interactions

rs4845625 lies within 5 kb of the Asp358Ala missense variant rs2228145 and is in partial LD with it. The Asp358Ala C allele drives the dominant functional effect at this locus (increased receptor shedding, enhanced trans-signaling, cardiovascular protection, asthma risk). rs4845625 contributes an independent, partially overlapping signal — its T allele tags a haplotype with elevated LDL and CRP, overlapping but not identical to the rs2228145 AA haplotype. Patients assessed for biologic therapy carry signal at both variants; together they give a more complete picture of baseline IL-6 receptor biology than either alone. rs12133641 is a third IL6R intronic variant approximately 6,216 bp from rs4845625 with its own bidirectional atopic/cardiovascular association, and rs4537545 is the direct haplotype partner of rs4845625 in the Arguinano 2017 analysis.

The melanocortin-4 receptor (MC4R) is the master satiety switch of the human hypothalamus. When activated by alpha-melanocyte stimulating hormone (α-MSH), MC4R signals to stop eating and ramp up energy expenditure. rs571312 sits upstream of the MC4R gene in the same regulatory block¹¹ regulatory block
a cluster of three variants — rs17782313, rs571312, and rs476828 — that lie in the distal linkage disequilibrium zone roughly 188 kilobases downstream of MC4R and collectively modulate its expression as the more extensively studied rs17782313. In Europeans, rs571312 and rs17782313 are in perfect linkage disequilibrium²² in perfect linkage disequilibrium
r²=1 in HapMap CEU, meaning the two SNPs are inherited together on the same haplotype block so completely that knowing one allele predicts the other with 100% accuracy.

Understanding rs571312 fills an important gap: while rs17782313 is the anchor variant in most European GWAS analyses, rs571312 was genotyped independently in key studies — including the Korean Genome Epidemiology Study and the Diabetes Prevention Program — and provides direct evidence linking the MC4R regulatory haplotype to food intake behavior rather than just adiposity outcomes. The A allele is the risk allele, associated with an ~18% increased obesity risk per allele (OR=1.18, 95%CI=1.15–1.21 per Xi et al. meta-analysis) and a documented increase in daily caloric consumption of approximately 60 kilocalories per allele.

The Mechanism

Like its haplotype partners, rs571312 is a non-coding regulatory variant. It does not change the MC4R protein itself but modulates how much MC4R the hypothalamus produces. The proposed mechanism mirrors what has been established for rs17782313: the A allele is associated with increased CpG methylation³³ CpG methylation
a chemical tag on DNA that silences gene expression — here reducing MC4R transcription in hypothalamic neurons at the MC4R promoter, leading to reduced receptor density in the appetite-regulating circuits of the arcuate nucleus and paraventricular nucleus. Fewer MC4R receptors means weaker responses to the leptin → POMC → α-MSH satiety cascade — a biological "deaf ear" to the hormonal signal that says "you've had enough."

The result is a phenotype characterized not by altered resting metabolic rate, but by subtly impaired satiety signaling — the brain continues receiving "keep eating" tone longer than it should after a meal. The Korean Genome Epidemiology Study⁴⁴ Korean Genome Epidemiology Study
8,830 Korean adults aged 40–69 with direct analysis of MC4R variants showed BMI was significantly higher with each additional A allele even after adjusting for age, sex, residence, energy intake, activity, and smoking. Crucially, this effect was amplified by mental stress — under high-stress conditions, the BMI difference between A allele carriers and CC homozygotes widened substantially.

The Evidence

The discovery-level evidence for rs571312 as an obesity risk variant comes from a 2009 childhood obesity study⁵⁵ 2009 childhood obesity study
Grant et al., examining 728 obese and 3,960 normal-weight European-American children that identified rs571312 as a perfect surrogate for rs17782313 (r²=1) conferring OR=1.14 for obesity in European Americans. The variant showed no significant association in African Americans (r²=0.149 with rs17782313 in that ancestry), a population-specific pattern that underscores the importance of haplotype architecture for interpreting its effects.

Beyond BMI, rs571312 has a documented behavioral footprint. The Diabetes Prevention Program analysis⁶⁶ Diabetes Prevention Program analysis
examining 3,180 adults at high risk for type 2 diabetes found that each additional A allele was associated with 61 extra kilocalories consumed per day (β=61.32, SE=26.24, P=0.019), replicating earlier findings from the Nurses' Health Study and Scottish cohorts. This positions rs571312 as a caloric intake amplifier — not dramatically, but persistently, across decades of meals.

The Korean cohort further showed a significant interaction between the MC4R variants and mental stress (p=0.0384): among individuals under high mental stress, A allele carriers had substantially higher BMIs than CC homozygotes, whereas under low-stress conditions the genetic effect was much smaller. This gene-environment interaction explains why stress management has biological, not just psychological, relevance for A allele carriers.

In a Chinese Northern Han study⁷⁷ Chinese Northern Han study
1,100 participants stratified by metabolic health status six MC4R-region SNPs including rs571312 were genotyped across metabolically healthy and unhealthy obese groups. The strongest signal came from rs2331841, where the AG genotype conferred 82% higher obesity risk (OR=1.82, P=0.030) and was associated with higher diastolic blood pressure. While rs571312 was genotyped, the study did not report a significant independent association for this variant specifically. The broader finding supports the MC4R region's involvement in metabolically unhealthy obesity⁸⁸ metabolically unhealthy obesity
obese with at least two additional cardiometabolic risk factors: elevated blood sugar, blood pressure, triglycerides, or low HDL-cholesterol through multiple linked variants.

Practical Implications

The caloric intake phenotype is particularly actionable. An extra 61 kcal/day per A allele sounds modest, but sustained over years it can substantially shift body weight trajectory — 61 kcal/day is roughly the caloric content of a small apple, compounding over time. Because the effect appears to operate through chronic caloric overconsumption rather than episodic bingeing, interventions that reduce baseline appetite or improve satiety signaling are well-suited to this variant.

Given the documented stress-MC4R interaction, cortisol-lowering strategies directly reduce the risk conferred by the A allele. Behavioral evidence from rs17782313 studies — which tag the same functional haplotype — shows that emotional eating patterns and binge eating under stress are elevated in MC4R risk allele carriers; the same interventions apply here.

Interactions

rs17782313 and rs12970134: rs571312 is in high LD with rs17782313 (r²=1 in European ancestry), meaning the two variants almost always co-occur on the same chromosome. Their effects are largely shared — rs571312 tags the rs17782313 risk haplotype in populations where these SNPs are genotyped differently. rs12970134 is a third regulatory variant in the same region, tagged by a related but distinct haplotype; it shows a particularly strong signal for waist circumference and insulin resistance, complementing rs571312's caloric intake signal. None of these three variants add independently in carriers who have all three — they are measuring overlapping variance in the same regulatory block.

FTO rs9939609: MC4R and FTO operate through distinct mechanisms (appetite signaling vs. thermogenesis), and their effects on obesity risk combine across the genome. A Chinese pediatric study found that individuals carrying risk genotypes at both loci had 2.45-fold increased obesity risk (OR=2.45, 95%CI=1.12–5.37) compared to carrying neither, with the two pathways providing complementary intervention targets.

CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4) is one of the immune system's most critical brakes. While much attention has focused on functional coding variants in CTLA4, the promoter also harbours a polymorphism that influences how much CTLA-4 is made in the first place. rs5742909, the -318C/T variant, sits 318 base pairs upstream of the CTLA4 transcription start site¹¹ CTLA4 transcription start site
Upstream variants in this position regulate transcription factor access and gene activation thresholds and modulates gene expression by altering promoter activity. The T allele is associated with higher CTLA-4 mRNA and cell-surface protein, potentially strengthening the immune checkpoint — and paradoxically this makes carriers more responsive to abatacept, a drug that mimics CTLA-4 function.

The Mechanism

The -318 position lies within a core promoter region that binds transcription factors controlling CTLA4 activation in T cells. Luciferase reporter assays have shown that the T allele produces significantly higher promoter activity²² T allele produces significantly higher promoter activity
Relative luciferase units: 8.13 ± 0.46 for T allele vs 6.87 ± 0.49 for C allele. More recent analysis identified LEF1 and TCF7 as transcription factors that bind differentially at this position³³ LEF1 and TCF7 as transcription factors that bind differentially at this position
Electrophoretic mobility shift assays show increased band intensity for the T allele, indicating stronger transcription factor binding, with the T allele enhancing TCF7-mediated transcriptional activation in Jurkat T cells.

In cellular expression studies, individuals carrying the T allele at -318 combined with the AA genotype at the exon 1 Thr17Ala position (rs231775)⁴⁴ AA genotype at the exon 1 Thr17Ala position (rs231775)
The two variants can act synergistically — the promoter variant controls transcription while the coding variant affects protein trafficking showed significantly higher CTLA-4 cell-surface expression after cellular stimulation and elevated CTLA-4 mRNA in non-stimulated cells. This suggests the -318T allele primarily upregulates basal transcription, while stimulation-induced expression is jointly regulated by both the promoter and coding regions.

The net functional result: T allele carriers have a modestly more active CTLA-4 checkpoint at baseline. Whether this constitutes protection from autoimmune disease or a subtle shift in immune tone depends strongly on the disease context and interacting genetic background.

The Evidence

Autoimmune disease associations — mixed picture: The -318C/T variant has been intensively studied across autoimmune conditions, and the overall conclusion is one of inconsistency across populations and diseases.

For Graves' disease and Hashimoto's thyroiditis, a meta-analysis of 29 independent studies including 3,614 cases and 8,839 controls⁵⁵ meta-analysis of 29 independent studies including 3,614 cases and 8,839 controls
Shi et al. 2018, published in Thyroid Research found no statistically significant association between the -318C/T polymorphism and Hashimoto's risk in any of the tested genetic models (allelic, codominant, dominant, or recessive). A large case-control study in Han Chinese⁶⁶ case-control study in Han Chinese
289 adult Graves' disease, 265 pediatric Graves', 229 pediatric Hashimoto's, 1,058 controls similarly found no association for -318C/T, while the +49A/G (rs231775) and CT60 (rs3087243) variants in the same gene showed significant risk.

For rheumatoid arthritis, a meta-analysis of 10 studies including 2,477 patients and 2,941 controls⁷⁷ meta-analysis of 10 studies including 2,477 patients and 2,941 controls
Comprehensive pooled analysis across Caucasian, Asian, and Latin American populations pooled results across multiple genetic models and found no significant association between rs5742909 and RA susceptibility in any ethnicity. The T allele OR for allelic comparison was 1.21 (95% CI 0.93–1.57, P=0.15), which did not reach significance. The -318 promoter variant is not the primary CTLA4 determinant of most autoimmune disease risk.

Abatacept pharmacogenomics — the strongest actionable signal: The most clinically relevant finding for rs5742909 comes from a retrospective cohort study of 109 RA patients⁸⁸ retrospective cohort study of 109 RA patients
Kowalska-Kępczyńska et al. 2020, MDPI Journal of Personalized Medicine treated with abatacept (a CTLA-4-Ig fusion protein used in biologic RA therapy). Patients carrying at least one copy of the T allele showed substantially better treatment outcomes: EULAR response at 12 months was associated with the T allele at OR = 5.88 (95% CI: 1.48–23.29), and achievement of low disease activity showed OR = 4.75. The same study identified rs231775 G allele as an independent predictor in the same dataset, suggesting the two CTLA4 variants may additively inform treatment selection. Remission rates were further improved in patients who initiated abatacept earlier and had fewer prior biologic failures.

This pharmacogenomic signal is biologically plausible: abatacept works by mimicking CTLA-4 and blocking CD28 co-stimulation of T cells. Patients whose T cells already express more CTLA-4 (T allele carriers) may have a disease phenotype particularly driven by co-stimulation pathways that abatacept targets, making the drug especially effective for them.

Practical Implications

For most people, the -318C/T variant is a background autoimmune susceptibility modifier rather than a primary disease determinant. The strongest single-SNP CTLA4 signals for autoimmune diseases — Graves', Hashimoto's, SLE, T1D — come from rs231775 (Thr17Ala) and rs3087243 (CT60), not from this promoter variant. The -318C/T result should be interpreted alongside those variants.

The clearest clinical application is in rheumatoid arthritis patients considering abatacept. If you carry the T allele, the available evidence — though from a single retrospective study — suggests meaningfully better odds of achieving EULAR response or low disease activity on abatacept. This is worth raising with a rheumatologist when discussing biologic treatment options, as CTLA4 genotyping is not yet routine practice but may inform treatment sequencing.

Interactions

rs5742909 is in partial linkage disequilibrium with rs231775 (Thr17Ala) and rs3087243 (CT60). The interaction between the -318T allele and rs231775 AA genotype is particularly notable: combined carriers show enhanced CTLA-4 expression above either variant alone⁹⁹ combined carriers show enhanced CTLA-4 expression above either variant alone
Studies of cell-surface CTLA-4 density show synergistic effects when both protective alleles are co-inherited. This means that interpreting rs5742909 in isolation is less informative than examining the full CTLA4 haplotype.

The CTLA4 locus also interacts epistatically with PTPN22 rs2476601, another T cell regulatory variant. In conditions like SLE and T1D, the combined CTLA4 + PTPN22 genotype profile confers a substantially different risk landscape than either gene alone.

For abatacept response in RA, co-carriage of the rs5742909 T allele and rs231775 G allele may be additive — the same study that identified rs5742909 as a predictor also found independent contributions from rs231775, consistent with these variants acting through partially complementary mechanisms (transcription vs. protein trafficking).

Von Willebrand factor is the body's universal bleeding stop. Released from the walls of blood vessels the moment they are damaged, VWF forms long threads that catch platelets and act as a scaffold for clot formation, while simultaneously carrying and protecting Factor VIII¹¹ Factor VIII
The clotting protein that haemophilia A patients are missing; VWF shields it from premature breakdown in the bloodstream. The VWF gene on chromosome 12 encodes this 2,813-amino-acid multimeric glycoprotein — one of the largest and most structurally complex proteins in human plasma.

The R1659X variant (also called c.4975C>T in transcript notation; the VWF gene is on the minus strand, so the plus-strand change is G→A at chr12:6,018,443) introduces a premature stop codon at amino acid position 1,659, abruptly truncating the protein within its central A2 domain. This is classified as pathogenic by the ClinGen von Willebrand Disease Variant Curation Expert Panel — the highest-confidence tier of genetic classification, supported by nine independent laboratory submissions.

The Mechanism

Normal VWF translation produces the full 2,813-residue precursor, which is then processed, multimerised in the Golgi, and stored in Weibel-Palade bodies ready for release. The R1659X stop codon creates a truncated mRNA transcript that is almost certainly degraded by nonsense-mediated decay (NMD)²² nonsense-mediated decay (NMD)
A cellular quality-control pathway that destroys mRNAs with premature stop codons before they can be translated — meaning the cell produces little or no protein from the affected allele at all, not merely a shorter non-functional protein.

The dose-response is clear and clinically exploited: one functional copy (AG genotype) produces enough VWF for partial function, causing von Willebrand disease type 1³³ von Willebrand disease type 1
Partial quantitative deficiency of VWF; typically VWF antigen 30–50% of normal with a mild-to-moderate bleeding phenotype. Two non-functional copies (AA genotype, homozygous or compound heterozygous) produce near-zero VWF — the defining feature of VWD type 3, the most severe form of the most common inherited bleeding disorder in the world.

The Evidence

The molecular identification of R1659X dates to 1992, when Zhang et al.⁴⁴ Zhang et al.
Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet, 1992. screened all 11 CGA (arginine) codons in the VWF gene of 25 type 3 VWD patients and identified this among the first documented homozygous point mutations causing severe disease. Heterozygous relatives of these patients consistently showed the milder type 1 phenotype — establishing the codominant inheritance pattern.

Population-level confirmation came from Gupta et al. (2008)⁵⁵ Gupta et al. (2008)
Genetic defects in von Willebrand disease type 3 in Indian and Greek patients. Blood Cells Mol Dis, 2008., who found R1659X to be one of the most frequent individual VWF defects among type 3 VWD patients of Indian and Greek origin, consistent with a mutation that likely arose once and has been propagated in multiple populations by carrier mating.

The variant is listed in ClinVar as pathogenic for hereditary von Willebrand disease (VCV000000297.13), meeting PVS1 (loss-of-function mechanism in VWD) and PP1 (co-segregation with disease across at least two affected families). Finnish patients documented in the ClinGen expert panel submission showed the full expected triad: pronounced bleeding tendency, low VWF antigen, and low Factor VIII levels.

In gnomAD, the A allele frequency is approximately 0.000007 in European non-Finnish populations and close to zero in all other ancestry groups, consistent with a rare pathogenic variant. The global prevalence of VWD type 3 (requiring two pathogenic alleles) is estimated at 1-3 per million.

Practical Actions

For heterozygous carriers (AG): the half-normal VWF level is usually sufficient to prevent spontaneous bleeding but may manifest as heavier-than-usual periods, easy bruising, or prolonged bleeding after surgery or dental procedures. Confirming VWF antigen (VWF:Ag) and ristocetin cofactor activity (VWF:RCo) with a haematologist is recommended before any planned invasive procedure, and desmopressin (DDAVP)⁶⁶ desmopressin (DDAVP)
A synthetic hormone that releases VWF from endothelial stores; the first-line treatment for type 1 VWD before surgery or dental work can transiently raise VWF levels 2-5 fold in most type 1 carriers, providing adequate haemostasis for minor procedures.

For homozygotes (AA): VWD type 3 requires prophylactic and on-demand treatment with VWF/FVIII concentrate⁷⁷ VWF/FVIII concentrate
Plasma-derived or recombinant products containing both VWF and Factor VIII, used to restore haemostasis in type 3 VWD. Desmopressin is ineffective because the endothelial VWF stores are absent. Ongoing care at a haemophilia treatment centre with a specialist haematologist is essential.

Both groups should inform all treating clinicians, surgeons, and dentists of the diagnosis before any procedure. Aspirin, NSAIDs, and other antiplatelet agents can significantly worsen bleeding and should be avoided or used only under specialist supervision.

Interactions

Blood group O (rs505922) independently lowers plasma VWF levels by approximately 25% compared to non-O blood types. A type 1 VWD carrier (AG at rs61750595) who also has blood group O may have substantially lower VWF:Ag than expected — the combined effect can push levels into a range that mimics moderate VWD. This interaction is clinically relevant when interpreting VWF laboratory results and when planning haemostatic management.

The Factor II G20210A variant (rs1799963) and Factor V Leiden (rs6025) are pro-thrombotic variants in the same coagulation pathway. While VWD itself is a bleeding disorder, the co-inheritance of a pro-thrombotic variant creates a clinically complex picture that warrants specialist input for any anti-thrombotic or anticoagulant therapy decisions.

CARD14¹¹ CARD14
Caspase Recruitment Domain family member 14; also called CARMA2; the gene responsible for the PSORS2 psoriasis susceptibility locus on chromosome 17q25 encodes a scaffold protein expressed primarily in keratinocytes — the cells that form the outer skin barrier. In response to inflammatory signals, CARD14 recruits BCL10 and MALT1²² BCL10 and MALT1
These proteins form the CBM signalosome; MALT1 also functions as a protease that cleaves NF-κB inhibitors, amplifying the inflammatory cascade to assemble a signaling complex that activates NF-κB³³ NF-κB
Nuclear Factor kappa-B; a master transcription factor that switches on dozens of pro-inflammatory genes including TNF-α, IL-17, IL-36γ, and chemokines like CXCL8. Gain-of-function mutations in CARD14 cause psoriasis and the related condition pityriasis rubra pilaris⁴⁴ pityriasis rubra pilaris
CAPE — CARD14-Associated Papulosquamous Eruption; a spectrum of inflammatory skin disease driven by constitutive NF-κB activation in keratinocytes by disrupting normal autoinhibition and locking the protein in an active state. The rare Glu422Lys substitution lies in the coiled-coil/LATCH linker region where most psoriasis-associated CARD14 mutations cluster, and was identified by Coto-Segura et al.⁵⁵ Coto-Segura et al.
A Spanish group studying pharmacogenomics of anti-TNF therapy in psoriasis as a variant enriched among patients who respond favorably to anti-TNF biologic treatment.

The Mechanism

Wild-type CARD14 maintains a self-inhibited conformation through its linker region (LR), which suppresses spontaneous BCL10 binding and NF-κB activation. Studies by Howes et al.⁶⁶ Howes et al.
Howes A, et al. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation. Biochem J. 2016;473:1759-68 showed that psoriasis mutations in this region — including E138A and G117S — abrogate the linker's inhibitory function by enabling constitutive BCL10 binding. Position 422 falls within the coiled-coil domain region (roughly residues 200–600) where autoinhibitory contacts are maintained. The Glu422Lys substitution replaces a negatively charged glutamate with a positively charged lysine, potentially disrupting the electrostatic environment that keeps the protein in its closed, autoinhibited state. No functional NF-κB reporter assay data specific to p.Glu422Lys exists in the published literature; the clinical association with anti-TNF response is the primary evidence for its functional relevance.

The mechanistic implication of an anti-TNF response association is that CARD14 Glu422Lys likely represents a partial gain-of-function variant⁷⁷ partial gain-of-function variant
Rather than fully constitutively active like E138A, the E422K mutation may lower the activation threshold without fully ablating autoinhibition — producing a keratinocyte NF-κB environment that is modestly TNF-α-overdriven and therefore preferentially responsive to TNF blockade. This parallels the mechanism seen with the common rs11652075 (Arg820Trp) variant at the same gene: both variants appear to mark a psoriasis subtype that is NF-κB/TNF-α-pathway-dominant and biologically matched to anti-TNF blockade.

The Evidence

The primary evidence comes from Coto-Segura et al. 2016⁸⁸ Coto-Segura et al. 2016
Coto-Segura P, et al. Common and rare CARD14 gene variants affect the antitumour necrosis factor response among patients with psoriasis. Br J Dermatol. 2016;175:134-41, which next-generation sequenced the entire CARD14 gene in 116 psoriasis patients treated with TNF inhibitors (79 responders, 37 non-responders; response defined as PASI 75 at week 24). Among responders, six patients were heterozygous p.Glu422Lys carriers versus zero non-responders (P=0.04). The effect is based on small numbers — six carriers across 116 patients — so while statistically significant, the confidence interval is wide and independent replication is essential.

The biological context strengthens the signal. Jordan et al. 2012⁹⁹ Jordan et al. 2012
Jordan CT, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. 2012;90:796-808 established that rare CARD14 missense variants are enriched in psoriasis cases (burden test p=0.0015 across >6,000 cases and >4,000 controls), with functional assays confirming NF-κB activation >2.5-fold above wild-type for the most pathogenic variants. The Glu422Lys variant predating its identification in the treatment cohort is consistent with it belonging to this class of functionally relevant rare alleles.

Practical Actions

Most carriers of this rare variant will have — or develop — some degree of plaque psoriasis or related CARD14-spectrum skin disease. The clinical signal from the Coto-Segura study is that if anti-TNF therapy (adalimumab, etanercept, infliximab) is being considered for moderate-to-severe psoriasis, Glu422Lys heterozygosity is a supporting biomarker for trial of these agents. No functional study has established the optimal dosing adjustment, and response is not guaranteed — PASI 75 response was observed in 6 out of a small cohort.

CARD14-associated psoriasis is also responsive to IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab), which target the downstream Th17 inflammatory output of the NF-κB cascade CARD14 activates. Case reports of CARD14-associated papulosquamous eruption show strong responses to both anti-IL-17 and anti-IL-23 therapy.

Interactions

This variant sits in the same gene as rs11652075 (Arg820Trp), the common CARD14 psoriasis pharmacogenomics marker. The two variants appear to tag the same biological theme — NF-κB overactivation in keratinocytes — from two different positions: one common (rs11652075, ~50% heterozygote frequency), one rare (Glu422Lys, <1% carrier frequency). The Coto-Segura study examined both variants in the same cohort, and the rare variant carriers contributed independently to anti-TNF response prediction. These are candidates for a compound action when larger cohorts confirm the combined signal.

The IL1A gene encodes Interleukin-1 alpha¹¹ Interleukin-1 alpha
IL-1α is a pro-inflammatory cytokine released from damaged cells that activates immune responses and promotes tissue remodeling, one of the most potent drivers of peritoneal inflammation in the body. In the context of endometriosis, IL-1α plays a central mechanistic role: it promotes adhesion of ectopic endometrial cells to the peritoneum, stimulates angiogenesis to nourish nascent implants, and recruits immune cells that paradoxically fail to clear the ectopic tissue. The rs6542095 variant near IL1A is the first genome-wide significant genetic link between the IL-1 inflammatory axis and endometriosis susceptibility.

The Mechanism

rs6542095 sits at chromosome 2, position 112,771,606 (GRCh38), approximately 2.3 kb upstream of the IL1A transcription start site (the gene is encoded on the minus strand, so this chromosomal distance places the variant in the 5' regulatory region). The functional consequence is classified as regulatory — the variant does not alter the IL-1α protein sequence, but rather is thought to influence IL1A promoter activity or transcriptional regulation, affecting how much IL-1α protein is produced in response to inflammatory stimuli.

IL-1α operates through a well-characterized pathway: upon cellular stress or damage, pre-IL-1α is released and binds the IL-1 receptor (IL-1R1), triggering NF-κB activation and a cascade of downstream inflammatory gene expression. In the peritoneal cavity of women with endometriosis, elevated IL-1α levels in peritoneal fluid²² elevated IL-1α levels in peritoneal fluid
Multiple studies have measured significantly higher IL-1 concentrations in the peritoneal fluid of women with active endometriosis compared to disease-free controls promote endometrial stromal cell survival, adhesion to mesothelial surfaces, and formation of the fibrous adhesions characteristic of advanced-stage disease. Genetic variants that upregulate IL1A expression would therefore be expected to amplify this inflammatory cascade and favor ectopic implant establishment.

The Evidence

The pivotal study was a meta-analysis of 3,908 endometriosis cases and 8,568 controls of European and Japanese ancestry³³ meta-analysis of 3,908 endometriosis cases and 8,568 controls of European and Japanese ancestry
Sapkota et al. Association between endometriosis and the interleukin 1A (IL1A) locus. Human Reproduction, 2015 that combined data from eight IL1A locus SNPs previously identified in small Japanese studies. The analysis found genome-wide significant association of rs6542095 with moderate-to-severe endometriosis (OR 1.21, 95% CI 1.13–1.29; p = 3.43 × 10⁻⁸), representing the first genome-wide significant evidence linking the IL-1 pathway to endometriosis susceptibility. Importantly, the association was restricted to moderate-to-severe disease (stages III/IV by revised American Fertility Society classification) — patients with mild endometriosis did not show a significant association. This stage-specificity aligns with the biology: IL-1α-driven peritoneal inflammation and adhesion formation are more characteristic of advanced-stage disease.

Independent replication was achieved in a Belgian cohort of 998 cases and 783 controls⁴⁴ Belgian cohort of 998 cases and 783 controls
Sapkota et al. Independent Replication and Meta-Analysis for Endometriosis Risk Loci. Twin Research and Human Genetics, 2015, where rs6542095 showed nominally significant association (p = 0.01 for grade B disease) and, when combined with the original dataset in meta-analysis, maintained genome-wide significance. A subsequent systematic review covering 35,022 endometriosis cases⁵⁵ systematic review covering 35,022 endometriosis cases
Cardoso et al. Systematic review of GWAS on susceptibility to endometriosis. EJOG Reproductive Biology, 2020 confirmed IL1A rs6542095 as one of five robustly replicated endometriosis susceptibility variants alongside WNT4, GREB1, FN1, and VEZT signals.

Replication has not been universal — a Polish cohort study did not find significant association in 315 cases — consistent with modest effect sizes that may be influenced by population composition and disease staging criteria.

Practical Actions

The C allele at rs6542095 is associated with elevated moderate-to-severe endometriosis susceptibility, not a diagnosis of endometriosis. The OR of 1.21 per C allele means CC homozygotes (two copies) carry approximately 1.46-fold elevated baseline risk at this locus compared to TT homozygotes. This is a meaningful but modest effect from a single variant. The most actionable implication is heightened vigilance for symptoms of moderate-to-severe endometriosis — precisely the stage that benefits most from early diagnosis before extensive adhesion formation occurs.

Because this variant specifically tags inflammatory-pathway susceptibility, it may also inform choices about managing peritoneal inflammation: progestin-based therapies reduce endometrial proliferation and can suppress IL-1-driven implant survival, and early laparoscopic excision removes the inflammatory foci before disease progresses.

Interactions

IL1B rs1143634 and IL1RN rs2234663: The IL-1 axis involves three proteins — IL-1α (encoded by IL1A), IL-1β (encoded by IL1B), and the IL-1 receptor antagonist (encoded by IL1RN) that competitively inhibits both. Women carrying both an IL1A risk allele (rs6542095-C) and a high-producing IL1B variant, or a low-producing IL1RN variant, may experience compounded peritoneal inflammation — the double burden of amplified IL-1 signaling with reduced natural counter-regulation. Formal compound-effect data are limited, but the pathway logic is well-established.

rs12700667 (near HOXA10/HOXA11): HOXA genes regulate endometrial differentiation and uterine receptivity. Risk alleles at the HOXA locus (rs12700667) combined with IL1A rs6542095-C could compound susceptibility through independent pathways — inflammatory implant survival (IL-1α) and defective endometrial patterning (HOXA).

rs1250248 (FN1): Fibronectin-1 mediates extracellular matrix remodeling and cell adhesion — both of which are promoted by IL-1α signaling in the peritoneum. Co-carriage of FN1 and IL1A risk alleles could synergize to favor ectopic tissue adhesion and invasion.

Your kidneys play a central role in regulating uric acid levels, filtering and selectively reabsorbing urate through specialised transporters in the proximal tubule. The SLC2A9 gene encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, a high-capacity voltage-driven urate transporter expressed in both the basolateral and apical membranes of the kidney proximal tubule; despite its name, GLUT9 transports urate far more efficiently than glucose. Variants in and around SLC2A9 consistently rank among the strongest genetic determinants of serum uric acid in genome-wide studies across multiple ancestries.

The rs7435196 variant is an intronic A>C change located at chromosome 4, position 9,965,932 (GRCh38), approximately 4.8 kilobases from the well-characterised SLC2A9 GWAS signal rs11942223. It lies deep within a large intron (c.681+14660 in coding notation) and does not alter the GLUT9 amino acid sequence. As of 2026, no genome-wide association studies or published clinical studies have reported a direct association between rs7435196 and uric acid levels, gout, or any other phenotype. The variant has zero citations in PubMed.

The Mechanism

rs7435196 is a non-coding intronic variant and does not directly change the GLUT9 protein. Its potential relevance derives from its position within the SLC2A9 locus — a region of the genome that harbours multiple independent signals for renal urate regulation. The SLC2A9 intronic region spanning positions 9.9–10.2 Mb on chromosome 4 contains regulatory elements, splice enhancers, and haplotype blocks that influence GLUT9 expression levels and transporter function. Non-coding variants in this region may alter transcription factor binding, affect mRNA splicing efficiency, or serve as proxies (via linkage disequilibrium) for causal regulatory variants nearby.

The proximity of rs7435196 to the established signal rs11942223 (~4.8 kb) raises the possibility that these variants partially tag the same regulatory haplotype block. However, this is not confirmed: the allele frequency distributions of the two variants differ substantially (rs11942223 shows T allele frequency ~74–78% in Europeans; rs7435196 shows A allele frequency ~57.6% in Europeans), suggesting they may not be in strong linkage disequilibrium and could represent distinct positions in the haplotype structure. Without published LD data specifically pairing rs7435196 with established SLC2A9 signals, whether this variant tags an independent or correlated effect cannot be determined.

The Evidence

There are no direct studies of rs7435196. What is known comes from the broader SLC2A9 literature:

Döring et al. (2008)²² Döring et al. (2008) conducted the landmark genome-wide association study that mapped the SLC2A9 intronic region as a major urate QTL, with variants in introns 4 and 6 explaining 1.2% of serum urate variance in men and up to 6% in women across German cohorts. The pronounced sex-specific effect was attributed to an interaction between SLC2A9 transporter regulation and estrogen's independent uricosuric action.

Vitart et al. (2008)³³ Vitart et al. (2008) independently replicated the SLC2A9 locus in Croatian and Scottish cohorts, establishing it as the strongest genetic region for serum uric acid in Europeans.

The allele frequency distribution of rs7435196 shows notable population heterogeneity: the C allele is common in African-ancestry populations (72%) but rare in East Asians (10.8%), while the A allele is more common in Europeans (57.6%). This pattern differs from the established risk signal at rs11942223 (where the T risk allele is uniformly common in Europeans, Africans, and South Asians at 74–78%, 55%, and 70% respectively), suggesting these variants may tag different underlying population history events rather than the same causal variant.

The evidence level for rs7435196 is emerging — the variant is in a gene with strong established relevance, but there are no direct association data for this specific rsid. Genotype-specific recommendations are based on the biological plausibility of the SLC2A9 locus, not proven effects of rs7435196 itself.

Practical Actions

Since the direct effect of rs7435196 on serum urate is uncharacterised, the practical guidance focuses on what is known to modulate urate levels through GLUT9-regulated renal excretion — the pathway where SLC2A9 variants exert their effect. The most impactful dietary interventions for urate management are: eliminating sugar-sweetened beverages (fructose both raises urate production and competes with urate for renal excretion), limiting purine-rich foods (organ meats, shellfish, beer), and increasing low-fat dairy intake (associated with modest urate reduction). These interventions apply regardless of SLC2A9 genotype but are most relevant when other SLC2A9 risk signals are present.

If you carry additional SLC2A9 risk variants (rs11942223 T allele or rs3733591 C allele) alongside this variant, the combined picture is more informative than any single variant alone.

Interactions

Within the SLC2A9 locus: rs7435196 is located 4.8 kb from rs11942223 and within the same broad intronic region as the established SLC2A9 urate signals. Without published LD data, whether these variants are correlated or independent is unknown. Carriers of risk alleles at the established signals (rs11942223 TT, rs3733591 CC) should weight those known-effect variants more heavily in assessing their SLC2A9 urate burden.

With ABCG2 rs2231142: ABCG2 regulates intestinal urate secretion through an entirely separate pathway from SLC2A9 renal reabsorption. These pathways are independent and additive: carrying risk alleles at both a renal reabsorption gene and an intestinal excretion gene produces higher serum urate than either alone.

Dietary fructose interaction: SLC2A9 intronic variants in this region have documented interactions with dietary fructose — the established signal at rs11942223 shows that C allele carriers lose their urate-clearance advantage under high fructose exposure. Whether rs7435196 participates in this interaction is unknown, but the proximity to rs11942223 makes it a reasonable precaution to limit sugar-sweetened beverages regardless of which specific SLC2A9 intronic variant is being examined.

The FCRL3¹¹ FCRL3
Fc receptor-like 3, a member of the immunoglobulin superfamily expressed at high levels on B cells and regulatory T cells; encodes a transmembrane receptor with multiple immunoreceptor tyrosine-based inhibitory and activation motifs (ITIMs and ITAMs) gene produces a surface receptor that modulates how B cells integrate activating and inhibitory signals. Unlike the classical Fc receptors that bind antibody constant regions to clear immune complexes, FCRL3 is expressed constitutively on B cells and plays a role in setting the threshold for B cell activation and autoantibody production. At position -169 in its promoter region, a C-to-T substitution (rs7528684) acts as a molecular volume knob: one variant drives higher FCRL3 transcription, the other does not. Which side of that switch a person carries matters for risk across multiple autoimmune diseases.

The variant is described in the literature as -169C>T using coding-strand notation (FCRL3 is transcribed from the minus strand of chromosome 1). In genome file notation (plus strand), the alleles are A and G, where the G allele corresponds to the coding C allele — the variant associated with higher FCRL3 expression and elevated autoimmune risk.

The Mechanism

The -169 position lies within an NF-κB²² NF-κB
nuclear factor kappa-light-chain-enhancer of activated B cells; a master transcription factor family that controls genes involved in immune activation, inflammation, and cell survival binding site in the FCRL3 promoter. The C allele (plus-strand G) creates a binding motif with higher affinity for NF-κB, leading to greater transcriptional activation of FCRL3 in B cells and regulatory T cells (Tregs). In the original discovery study, individuals carrying the risk genotype showed measurably higher FCRL3 protein expression on their B cells and produced greater quantities of autoantibodies — the antibodies that attack self-tissues in diseases like rheumatoid arthritis and Hashimoto's thyroiditis.

FCRL3 overexpression on Tregs is particularly significant. Regulatory T cells normally suppress autoreactive immune responses; elevated FCRL3 on Tregs appears to impair their suppressive capacity, likely by modulating FOXP3 expression. A 2026 study confirmed that CC genotype carriers show downregulated FOXP3 and IL-35³³ CC genotype carriers show downregulated FOXP3 and IL-35
FOXP3 is the master transcription factor of regulatory T cells; IL-35 is an anti-inflammatory cytokine produced by Tregs that suppresses effector T cell responses; both are reduced in CC carriers, disrupting immune tolerance alongside elevated FCRL3, creating a dual loss of tolerance mechanisms: hyperactive B cells producing autoantibodies combined with impaired Treg suppression.

The Evidence

The variant was first identified by Kochi et al. in Nature Genetics (2005)⁴⁴ Kochi et al. in Nature Genetics (2005)
Kochi Y, Yamada R, Suzuki A et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nature Genetics 37:478–485 in a Japanese cohort of 830 RA cases and 658 controls, with an odds ratio of 2.15 (P=8.5×10⁻⁷) for rheumatoid arthritis. The same study found associations with Graves' disease (autoimmune hyperthyroidism) and SLE, positioning FCRL3 as a pleiotropic autoimmune susceptibility gene rather than a disease-specific variant.

An updated meta-analysis of 34 case-control studies⁵⁵ updated meta-analysis of 34 case-control studies
Yang Y, Su X, Zhang K, Zhou R. The Fc receptor-like 3 gene polymorphisms and susceptibility to autoimmune diseases: an updated meta-analysis. Autoimmunity 46:547–558, 2013 confirmed significant associations of rs7528684 with RA, Graves' disease, and type 1 diabetes. Carriers of TC or TT genotypes showed approximately 9% lower odds of autoimmune diseases compared to CC carriers (OR=0.91, 95% CI 0.85–0.97) — indicating that having even one copy of the lower-expression T allele (plus-strand A) provides partial protection against CC-level risk.

For rheumatoid arthritis specifically, a Chinese case-control study of 630 RA patients and 696 controls, combined with meta-analysis⁶⁶ Chinese case-control study of 630 RA patients and 696 controls, combined with meta-analysis
Lin X, Zhang Y, Chen Q. FCRL3 gene polymorphisms as risk factors for rheumatoid arthritis. Human Immunology 77:301–306, 2016 found CC vs TT genotype OR=1.62 (95% CI 1.18–2.22) and C allele vs T allele OR=1.32 (95% CI 1.12–1.54), with the association strongest in Asian populations.

The picture is more nuanced for SLE. A meta-analysis of nine case-control studies (2,544 SLE cases, 3,913 controls)⁷⁷ meta-analysis of nine case-control studies (2,544 SLE cases, 3,913 controls)
2013 meta-analysis found no significant overall association between the C allele and SLE risk in European or Asian populations, though a single Latin American study showed CC vs TT OR=2.69. The effect appears ethnically heterogeneous, with the strongest and most consistent signals in East Asian populations where it was originally discovered.

Practical Implications

The risk conferred by this variant operates through immune tolerance mechanisms — the balance between B cell activation and Treg suppression — rather than through a specific inflammatory pathway like the cytokine-targeted pathways of PTPN22 or HLA variants. This means the downstream consequences span multiple autoimmune diseases rather than predicting a single condition.

Individuals carrying one or two G alleles (plus-strand) have a biological basis to be more alert to early symptoms of the autoimmune conditions linked to elevated FCRL3: joint stiffness and synovitis (RA), thyroid dysfunction (Graves' disease, Hashimoto's thyroiditis), and systemic symptoms (SLE). The variant does not predict which specific disease will manifest, but it does point toward conditions where impaired B cell tolerance and autoantibody production are central.

Monitoring thyroid function (TSH, free T4) and inflammatory markers periodically is a reasonable approach for GG homozygotes or those with family history of FCRL3-linked conditions.

Interactions

FCRL3 rs7528684 converges on the same B cell activation and tolerance pathway as rs2476601 in PTPN22 (R620W). PTPN22 R620W impairs a phosphatase that normally dampens B cell receptor signalling; elevated FCRL3 from the rs7528684 G allele adds further B cell dysregulation through a different mechanism (NF-κB-driven transcription vs. signalling phosphatase loss). Carriers of both risk variants may have compounded B cell autoreactivity. CTLA4 rs3087243 (CT60) modulates T cell co-inhibition and has been studied alongside FCRL3 in Graves' disease susceptibility in Japanese populations.

Your kidneys decide whether blood pressure rises or stays stable on a high-salt diet. A key player in that decision is NBCe2¹¹ NBCe2
sodium-bicarbonate cotransporter electrogenic family member 2, encoded by the SLC4A5 gene in the proximal tubule. NBCe2 normally sits quietly in the Golgi apparatus, but when intracellular sodium climbs — as it does when you eat a salty meal — the transporter migrates to the apical membrane and accelerates coupled sodium-bicarbonate reabsorption back into the bloodstream. rs7571842 sits in an intron of SLC4A5 and modifies how aggressively this mechanism operates.

The Mechanism

Under high-sodium conditions, the rs7571842 A allele increases binding of HNF4A²² HNF4A
hepatocyte nuclear factor 4-alpha, a transcription factor that regulates metabolic genes in the liver and kidney to the SLC4A5 locus. This aberrant HNF4A-mediated upregulation enhances NBCe2 surface expression and activity in the proximal tubule, driving greater sodium reabsorption. The net result: more sodium retained, higher plasma volume, and amplified blood pressure on high-sodium diets. The G allele is associated with attenuated transporter expression and a blunted blood pressure response to sodium loading.

The Evidence

The foundational study by Carey RM et al.³³ Carey RM et al.
"Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate cotransporter." Hypertension, 2012 put 185 white participants through a controlled dietary protocol (7 days at 10 mmol/day sodium, 7 days at 300 mmol/day) and found rs7571842 was one of the strongest genetic predictors of salt sensitivity, with the G allele conferring protection (OR=0.221, P=1.0×10⁻⁴). The finding replicated in an independent hypertensive cohort, with meta-analysis confirming the association (P=1.2×10⁻⁵).

A smaller controlled trial by Pilic & Mavrommatis⁴⁴ Pilic & Mavrommatis
"Genetic predisposition to salt-sensitive normotension and its effects on salt taste perception and intake." British Journal of Nutrition, 2018 quantified the effect in normotensive individuals: AA carriers showed the largest blood pressure increase on high sodium — +7.75 mmHg systolic (P=0.002, Cohen's d=2.4) and +6.25 mmHg diastolic (P=0.044) — a clinically meaningful difference. The mechanistic basis was confirmed by Gildea JJ et al.⁵⁵ Gildea JJ et al.
"Sodium bicarbonate cotransporter NBCe2 gene variants increase sodium and bicarbonate transport in human renal proximal tubule cells." PLoS One, 2018, who demonstrated that cells carrying the variant showed significantly greater bicarbonate- dependent pH recovery and sodium transport.

Earlier work in the HERITAGE Family Study (Stütz AM et al.⁶⁶ Stütz AM et al.
"Functional identification of the promoter of SLC4A5, a gene associated with cardiovascular and metabolic phenotypes." European Journal of Human Genetics, 2009) found rs7571842 associated with resting and submaximal exercise pulse pressure (P=0.002–0.003) in 503 White participants, extending the finding beyond resting blood pressure.

Practical Actions

Salt sensitivity affects an estimated 25–30% of the adult population and is a major contributor to hypertension that does not respond to standard lifestyle advice. AA carriers of rs7571842 have a specific renal mechanism that amplifies the blood-pressure response to dietary sodium — standard guidelines recommending 2,300 mg/day may not adequately protect this group. The evidence from Carey et al. and Pilic & Mavrommatis consistently points to a substantially greater blood pressure benefit from stricter sodium restriction (targeting ≤1,500 mg/day, the threshold already recommended for people with established hypertension) compared to carriers of the protective G allele.

Tracking 24-hour urine sodium excretion is the most accurate way to quantify actual intake — spot urine sodium or diary estimates consistently underestimate consumption by 30–50%. Ambulatory blood pressure monitoring captures the salt-loading effect that clinic readings miss.

Interactions

rs7571842 and the nearby rs10177833 (also in SLC4A5, ~3 kb upstream) showed comparable effect sizes and were the two strongest SLC4A5 signals in the Carey 2012 study. Both SNPs are in partial linkage disequilibrium; compound effects in individuals carrying risk alleles at both sites have not been fully characterized. Future compound action candidates exist between rs7571842 and rs10177833.

The SRD5A2 gene encodes steroid 5-alpha-reductase type 2, the enzyme that converts testosterone into dihydrotestosterone (DHT) — the androgen driving prostate growth, scalp hair loss, and male external genital development in utero. Variants in SRD5A2 that alter enzyme activity or expression can shift how much DHT an individual produces throughout life, with downstream effects on androgen-sensitive tissues. The rs7594951 variant lies deep within intron 4 of SRD5A2 on chromosome 2 (GRCh38 position 31,566,723). The SRD5A2 gene runs on the minus strand; in the coding-strand frame this is a G>A change, while in genome files (WGS and consumer chips including 23andMe) it appears as the plus-strand C>T variant described here.

The Mechanism

As an intronic variant, rs7594951 does not alter the SRD5A2 protein sequence directly. Instead, it may affect pre-mRNA splicing, intronic enhancer elements, or mRNA stability — mechanisms known to modify the final amount of functional enzyme produced from a gene. The precise molecular mechanism has not been characterized in published literature, making this a variant of [emerging | an association identified in a single moderately-sized study that requires replication in larger cohorts] evidence status rather than an established functional variant.

SRD5A2 is the dominant 5-alpha-reductase isoform in the prostate, seminal vesicles, epididymis, and fetal external genitalia. Its activity level determines how much DHT is produced locally in androgen-sensitive tissues — and therefore how sensitive those tissues are to androgenic stimulation.

The Evidence

The primary evidence linking rs7594951 to DHT metabolism comes from a 2010 study by Setlur et al. examining 426 Austrian men (205 controls, 221 prostate cancer cases) for variants in DHT-metabolizing genes¹¹ Setlur et al. examining 426 Austrian men (205 controls, 221 prostate cancer cases) for variants in DHT-metabolizing genes
Setlur SR et al. Cancer Epidemiol Biomarkers Prev. 2010;19(1):229-39. Men in the control group who carried the AA genotype in the paper's coding-strand notation — corresponding to the TT genotype in plus-strand notation — tended toward higher serum DHT levels (P = 0.03). This suggests the minor T allele, or a variant in strong linkage disequilibrium with it, is associated with modestly increased 5-alpha-reductase activity or efficiency, resulting in more testosterone being converted to DHT.

rs7594951 was also among the SRD5A2 tag SNPs examined in a 2014 population-based study by Carmichael et al. investigating sex hormone gene variants in hypospadias — a congenital defect of the male urethra caused by insufficient androgenization during fetal development²² Carmichael et al. investigating sex hormone gene variants in hypospadias — a congenital defect of the male urethra caused by insufficient androgenization during fetal development
Carmichael SL et al. Andrology. 2014;2(1):130-7. The study genotyped 332 tagSNPs across 20 sex hormone metabolism genes in 633 cases and 855 controls born in California. Ten SRD5A2 SNPs showed p < 0.01 in single-SNP analyses; three SRD5A2 haplotype blocks showed odds ratios of 1.4–1.7 for hypospadias. While the paper reports haplotype blocks rather than individual SNP effects for rs7594951, the direction is consistent with DHT availability during genital development influencing hypospadias risk. The effect direction here is opposite to the DHT-level finding: haplotypes conferring lower SRD5A2 function associate with higher hypospadias risk (less DHT during fetal development impairs urethral fusion), while the TT genotype at rs7594951 may associate with higher DHT.

The overall evidence base for rs7594951 as an independent causal variant is limited to these two studies, neither of which reports rs7594951 in isolation with a definitive effect size. The variant should be understood as a possible marker of 5-alpha-reductase activity variation rather than a clinically established risk allele.

Practical Implications

If the minor T allele does increase local DHT production — consistent with the Setlur 2010 findings — CT and TT carriers may experience somewhat stronger androgenic effects in DHT-sensitive tissues over their lifetime. This could manifest as more pronounced androgenetic alopecia in genetically predisposed individuals, a modestly greater tendency toward benign prostatic hyperplasia with age in men, or potentially higher baseline DHT levels on serum hormone testing. The effect magnitude is likely modest given the intronic location and the minor allele frequency of ~10.7%.

For individuals prescribed finasteride (for hair loss or BPH) or dutasteride, intrinsic 5-alpha-reductase activity level at baseline may influence the degree of DHT suppression achieved at standard doses — higher baseline activity could theoretically require different titration. This is speculative at the individual SNP level, as pharmacogenomic data for rs7594951 specifically are not available.

Regarding hypospadias, the developmental window during which DHT levels matter (weeks 8–16 of gestation) is not modifiable postnatally. The hypospadias association is of academic and family planning interest but does not inform actionable intervention in adults.

Interactions

rs7594951 sits in the same gene as the better-characterized V89L variant (rs523349) and the A49T variant (rs9282858). The V89L variant reduces SRD5A2 enzyme activity by approximately 30%, and A49T also alters enzyme kinetics. Haplotypes combining rs7594951 with these coding variants may produce combined effects on DHT output that differ from either variant alone. Literature on the specific haplotype structure involving all three variants is limited, but the SRD5A2 locus should be interpreted as a unit across these SNPs where possible.

The CYP17A1 variant rs743572 influences androgen precursor production upstream of SRD5A2, and variants in the androgen receptor (AR) gene modulate DHT sensitivity in target tissues downstream. Individuals with multiple variants affecting DHT production or response may experience amplified or attenuated androgen-sensitive phenotypes.